The most profound shift in metabolic health in a generation is not just happening in pharmacies and clinics. It is reshaping grocery aisles and kitchen pantries, creating a multi-billion dollar market for foods designed to work alongside, or even in place of, blockbuster drugs. Into this space steps Lembas, an Israeli startup with a simple, ambitious proposition: what if you could stimulate the body's own appetite-regulating hormones with a peptide you could bake into a snack bar? [AgFunderNews, June 2025]
Founded in 2024, Lembas emerged from stealth last June with a $3.6 million pre-seed round. Its first product is GLP-1 Edge, a patent-pending bioactive peptide powder it offers to food and supplement brands as a business-to-business ingredient. The company's bet is that its AI-driven discovery platform can find and design food-grade peptides that safely enhance the body's natural production of GLP-1 and other satiety hormones, offering a non-pharmaceutical path to metabolic support [AgFunderNews, June 2025] [Forbes, June 2025].
The Computational Discovery Wedge
Lembas is not trying to brew a new drug. Its differentiation rests on a licensed technology from Tel Aviv University that uses artificial intelligence to discover, design, and screen thousands of bioactive peptides [AgFunderNews, June 2025]. This computational approach, the company argues, allows it to move faster and more precisely than traditional food science R&D, which might rely on slower, more serendipitous discovery methods.
The output is an ingredient, not a finished consumer product. Lembas plans to sell GLP-1 Edge powder to manufacturers who can formulate it into shakes, bars, beverages, and snacks. The company reports its scientists have demonstrated positive results in stimulating GLP-1 secretion in cell and animal models, though human clinical data is still pending [Green Queen]. This B2B model allows Lembas to focus on its core competency of peptide discovery and avoid the capital-intensive work of building a consumer brand and supply chain from scratch.
A Team Built for Deep Tech Translation
The founding team brings together serial entrepreneurship and deep scientific expertise, a combination crucial for navigating the intersection of biotech, AI, and regulated food ingredients.
| Role | Name | Key Background |
|---|---|---|
| CEO & Co-Founder | Shay Hilel | Serial entrepreneur with prior leadership roles at Biotax and BrainVu (acquired by Mantis-Vision) [Shay Hilel (@shilel) / X]. |
| CTO & Co-Founder | Dr. Zohar Barbash | Geneticist with a PhD in molecular biology from Tel Aviv University; leads the combined biology and AI effort [Forbes, June 2025] [Zohar Barbash - Lembas |
| CSO & Co-Founder | Prof. Maayan Gal | Scientific background from the Weizmann Institute of Science; previously a scientific advisor and co-founder at ProJini AgChem [Maayan Gal - Crunchbase Person Profile]. |
| Co-Founder | Dr. Daniel Bar | Co-founding team member [United with Israel]. |
CEO Shay Hilel's track record in bringing deep tech ventures to market provides commercial heft, while Dr. Barbash and Prof. Gal anchor the scientific credibility. The team's stated mission is to develop a convenient, natural method for stimulating GLP-1, moving beyond invasive injections [United with Israel].
Riding the GLP-1 Companion Tailwind
The market Lembas is entering is not hypothetical. The global surge in usage of GLP-1 receptor agonist drugs like Ozempic and Wegovy has catalyzed an entirely new food category. Consumers on these medications often experience reduced appetite and specific nutrient needs, driving demand for products that are high in protein, fiber, and essential vitamins.
Market researchers project explosive growth. The global GLP-1 companion foods market was valued at $2.90 billion in 2025 and is estimated to reach $3.60 billion this year. It is projected to swell to $16.58 billion by 2036, representing a compound annual growth rate of 16.5% [GlobeNewswire, October 2026]. Major food conglomerates like Nestlé have already launched dedicated product lines, such as its Vital Pursuit frozen meals, signaling serious corporate investment in the space [Forbes, May 2024].
Lembas's pre-seed funding, led by FLORA Ventures with participation from Bluestein Ventures, Fresh Fund, and others, is a vote of confidence in this specific wedge: providing the innovative ingredient that powers these new product formulations [AgFunderNews, June 2025].
The Regulatory and Commercial Hurdles Ahead
For all its promise, Lembas's path is lined with significant, standard challenges for a novel food ingredient. The company's technology and early data have attracted investor interest, but the journey from lab to supermarket shelf is long.
The primary risks are both scientific and commercial:
- Clinical validation. Positive cell and animal model results are a necessary first step, but they are not predictive of human efficacy or safety. The planned human clinical trial will be the critical proof point for GLP-1 Edge's biological activity in people [AgFunderNews, June 2025].
- Regulatory pathways. As a food ingredient, GLP-1 Edge will need to secure Generally Recognized as Safe (GRAS) status from the U.S. FDA or equivalent approvals in other markets. This process is rigorous and can be lengthy.
- Formulation and adoption. Even with regulatory clearance, the ingredient must prove it is stable, tasteless, and effective in final food products. Convincing large, conservative food brands to reformulate with a novel ingredient requires demonstrating clear consumer demand and a compelling cost-benefit analysis.
The company's most plausible answer to these challenges is its team's experience and its capital-efficient B2B approach. By partnering with established manufacturers, Lembas can use their formulation expertise and distribution networks, reducing its own risk and capital burn.
The Next Twelve Months
The immediate roadmap for Lembas is clear. The proceeds from its pre-seed round are likely earmarked for advancing its science and initiating key commercial conversations. The most important milestone to watch will be the initiation and results of its first human clinical study. Positive data would not only de-risk the core science but also become a powerful tool for engaging potential manufacturing partners.
Commercial traction will be measured not by consumer sales, but by signed development agreements or pilot projects with food and supplement companies. The company has already reported attracting interest from global brands, though it has not named specific partners [AgFunderNews, June 2025]. A logical next financing step would be a seed round to fund expanded clinical work and early commercial deployment, likely contingent on demonstrating progress on these fronts.
For patients and consumers, the potential appeal is straightforward. The current standard of care for significant weight management and type 2 diabetes increasingly involves weekly injectable GLP-1 drugs, which can be costly, subject to supply shortages, and accompanied by side effects. A food-based ingredient that offers a gentler, more accessible form of metabolic support would represent a meaningful alternative or complement for a broad population. Lembas is betting that its AI can find the peptide that makes that alternative possible, turning a computational discovery into an ingredient that could one day be part of daily life for millions.
Sources
- [AgFunderNews, June 2025] Pharma is eating Big Food’s lunch. Lembas fights back with GLP-1-boosting peptide | https://agfundernews.com/pharma-is-eating-big-foods-lunch-lembas-fights-back-with-glp-1-boosting-peptide
- [Forbes, June 2025] Lembas GLP-1 Ingredient Manufacturer Enters The Market Following $3.6 Million Pre-Seed Investment | https://www.forbes.com/sites/andrewwatman/2025/06/10/lembas-glp-1-ingredient-manufacturer-enters-the-market-following-36-million-pre-seed-investment/
- [GlobeNewswire, October 2026] Global GLP-1 Companion Foods Market Size, Share, Trends, and Forecast 2026-2036 | https://www.globenewswire.com/news-release/2026/10/28/3390453/28124/en/global-glp-1-companion-foods-market-size-share-trends-and-forecast-2026-2036-industry-to-reach-us-16-58-billion-as-protein-rich-innovation-and-telehealth-expansion-drive-16-5-cagr.html
- [Green Queen] Lembas company profile | https://www.greenqueen.com.hk/company/lembas/
- [United with Israel] Lembas company profile | https://unitedwithisrael.org/company/lembas/
- [Shay Hilel (@shilel) / X] Shay Hilel's X profile | https://twitter.com/shilel
- [Zohar Barbash - Lembas | LinkedIn] Zohar Barbash's LinkedIn profile | https://www.linkedin.com/in/zohar-barbash-173b771a/
- [Maayan Gal - Crunchbase Person Profile] Maayan Gal's Crunchbase profile | https://www.crunchbase.com/person/maayan-gal
- [Forbes, May 2024] Weight Loss Drug Boom Won't Eat Into Food Industry Profits, Nestlé CEO Says | https://www.forbes.com/sites/roberthart/2024/05/30/weight-loss-drugs-wont-eat-into-food-industry-profits-nestl-ceo-says/